Pharma IQ Members


Discover results-proven tools and methodologies for your clinical development. Learn how to improve your trial design, data collection and clinical supply. In addition, get key information on how to improve your patient recruitment and retention. Pharma IQ is proud to provide an international, non-biased, central resource, for professionals working in clinical development to exchange ideas on best practice and share case studies on innovation within the area.

Contributor: Chanice Henry
Posted: 28/04/2016
Chanice Henry
In order to examine the therapy which has been labelled as a game changing addition to oncology, earlier this month industry stakeholders met to explore the evidenced potential of immune checkpoint modulation therapies. The two day conference also saw attendees discuss and formulate tactics to scale the roadblocks encountered by the therapy. Full Article »
Posted: 21/10/2013
Experiences with IRT- An Interview with CTS manager Michael Pompey
Ahead of the Clinical Trial Supply Europe event, Pharma IQ presents interviews filmed live at last year's CTS event. In this interview Michael Pompey talks about the daily challenges he faces as a clinical trial supply manager at Sandoz and he discusses his experience with IRT. Full Video »
Contributor: Gerald Clarke
Posted: 01/10/2013
For Dr Hella Kohlhof, the study of epigenetics was not love at first sight, however the potential it posesses eventually won her over. Now Dr Kohlhof is Manager of Translational Pharmacology at 4SC AG and is applying epigenetic knowledge in a phase 1 first-in-man trial. She talks to us about what role epigentics plays in cancer and how new Full Podcast »
Contributor: George Clinical Representative
Posted: 22/03/2016
The rising presence of clinical trials (CT) in the Asia-Pacific region is predominantly driven by the East Asian region which includes China, Japan, Korea, Taiwan and Hong Kong. Over the past decade, Korea has become a global clinical trial hub and is one of the leading clinical trial destinations in the Asian region; with approximately 80% of its CTs being multinational trials from 2001-2012. Full Column »
Contributor: Miss Chanice Henry
Posted: 15/03/2016
Miss Chanice Henry
On the route to creating new therapeutics for patients, pharma firms require access a range of diverse biological samples. However, one challenge for the market is locating collaborations that will provide a channel to diverse and high quality samples. This is mirrored by the intentions of both public biobanks and academic or hospital biobanks which have a strong focus on hosting and distributing good quality samples that are of high usability in the eyes of biopharma firms. Full Whitepaper »